Indivior Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 1243.03, 1301, 1369.66, 1405.6, 1464.8 ], "ebit_estimate": [ 602.5, 650.44, 698.6, 674, 714.1 ], "ebitda_estimate": [ 630.88, 679.5, 726.95, null, null ], "net_income_estimate": [ 461.98, 493.44, 531.7, 483.9, 515.7 ], "per_share_eps_estimate": [ 3.27, 3.88, 4.32, null, null ], "eps_nri_estimate": [ 3.66, 3.87, 4.18, 3.91, 4.22 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 0.23, 2.34, 6.52, null, null ], "pretax_income_estimate": [ 592.83, 641.53, 677.5, 609.4, 649.4 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ 228.52, 312.49, 102.59, null, null ], "gross_margin_estimate": [ 85.3, 85.47, 85.5, 86, 86 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 12.39, 10.44, 9.38, null, null ], "long_term_growth_rate_mean": 17.32, "long_term_revenue_growth_rate_mean": "3.52", "future_per_share_eps_estimate_growth": 36.03, "future_eps_nri_estimate_growth": 17.32, "future_revenue_estimate_growth": 3.52, "future_ebit_estimate_growth": 17.81, "future_ebitda_estimate_growth": 18.1, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 17.22, "future_pretax_income_estimate_growth": 18.14, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -73.88, "future_gross_margin_estimate_growth": 0.57, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 306.55, 314.53, 322.38, 311.67, 323.97, 336.03, 343.03, 340.2 ], "ebit_estimate": [ 144.57, 152.3, 164.63, 149.65, 168.5, 175.05, 180.55, 157.3 ], "ebitda_estimate": [ 149.25, 161.4, 174.05, 151.95, 171.1, 183.8, 188.65, 159.6 ], "net_income_estimate": [ 113.1, 119.23, 129.03, 120.15, 134.9, 140.05, 144.35, 124.1 ], "per_share_eps_estimate": [ 0.79, 0.85, 0.94, 0.81, 0.97, 1.02, 1.08, 0.89 ], "eps_nri_estimate": [ 0.87, 0.92, 1, 0.98, 1.03, 1.08, 1.11, 0.96 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ 140.5, 147, 157.7, 162.3, 172.7, 178.4, 179.1, 147.5 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 84.5, 84.43, 84.83, 85.05, 85.25, 85.25, 85.25, 86 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 11.95, 11.34, 10.83, 10.44, 10.23, null, null, null ], "long_term_growth_rate_mean": 17.32, "long_term_revenue_growth_rate_mean": "3.52", "future_per_share_eps_estimate_growth": 36.03, "future_eps_nri_estimate_growth": 17.32, "future_revenue_estimate_growth": 3.52, "future_ebit_estimate_growth": 17.81, "future_ebitda_estimate_growth": 18.1, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 17.22, "future_pretax_income_estimate_growth": 18.14, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -73.88, "future_gross_margin_estimate_growth": 0.57, "future_operating_cash_flow_per_share_estimate_growth": null }